Pick fecal microbiota transplantation to enhance therapy for major depressive disorder.

In recent years, fecal microbiota transplantation (FMT) has emerged as a promising therapy for major depressive disorder (MDD). The goal of the operation is to restore a healthy gut microbiota by introducing feces from a healthy donor into the recipient's digestive system. The brain-gut axis is thought to have a significant role in regulating mood, behavior, and cognition, which supports the use of FMT in the treatment of MDD. Numerous studies have shown a correlation between abnormalities of the gut microbiota and MDD, whereas FMT has demonstrated the potential to restore microbial equilibrium. While FMT has shown encouraging results, it is crucial to highlight the potential hazards and limits inherent to this therapeutic approach. Stool donor-to-recipient disease transfer is a concern of FMT. Furthermore, it still needs to be determined what effect FMT has on the gut microbiota and the brain in the long run. This literature review provides an overview of the possible efficacy of FMT as a therapeutic modality for MDD. There is hope for patients who have not reacted well to typical antidepressant therapy since FMT may become an invaluable tool in the treatment of MDD as researchers continue to examine the relationship between gut microbiota and MDD. • Gut microbiota could play a significant role in developing and treating major depressive disorder (MDD). • Fecal microbiota transplantation (FMT) has shown promise as a therapy for various gut-related conditions. • FMT can improve mood and cognitive function in patients with MDD. • While the use of FMT for MDD is still in the early stages, it is an exciting area of study that holds promise for the future of MDD. [ABSTRACT FROM AUTHOR]